Insulin syringes market was valued at $1,561.20 million in 2020, and is projected to reach $2,401.51 million by 2030, registering a CAGR of 4.4% from 2021 to 2030. An insulin syringe aids in delivering insulin to diabetic patients in required doses. The insulin syringes consist of three parts-a needles, a barrel, and a plunger, and is available in various sizes. The needle is usually thin and short and covered with a special material such as silicone in order to allow it to slide through the skin causing minimal pain. Barrel is the chamber that holds the insulin. It is marked with calibrations designed to show the units of insulin being injected. The plunger is the narrow rod that slides up and down the length of the barrel. it serves to either draw the insulin into the barrel or release the insulin from the barrel through the needle. Further, the size of the insulin syringe is selected based on the desired dosage of insulin to be administered to diabetic patients.
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
Novo Nordisk A/S, , Biocon Ltd Abbott Laboratories, Terumo Corporation, Cardinal Health Inc, Beckton and Dickinson Company, Eli Lilly and Company, Nipro Medical Corporation, Medline Industries and Hindustan syringe and medical device Ltd The other players in the value chain (not included in the report) are Medtronic., Sanofi S.A and Braun Melunsun
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/3740
๐๐ผ๐๐ถ๐ฑ-๐ญ๐ต ๐ฆ๐ฐ๐ฒ๐ป๐ฎ๐ฟ๐ถ๐ผ:
The overall impact of COVID -19 remain positive for insulin syringe market. As patients with different health issues such as, diabetes, and high blood pressure are at higher risk of getting affected by this virus. It is found that the mortality rate is high in a patient with diabetes compared to the general population. The people living having diabetes require continuous access to insulin (administrated with syringes or pens) and care. Without or irregular supply of insulin devices due to pandemic can seriously affect the health of a person with diabetes especially who are diagnosed with type-1 diabetes as they are totally dependent on insulin. In addition, according to National Center of Biotechnology Information diabetes is treated with angiotensin converting enzymes inhibitors and this has been discovered that coronavirus binds to the target cells through this enzyme, an enzyme expressed in the blood vessels and lungs. As an increasing level of ACE2 enzyme founded in diabetic patients, the chances of COVID-19 also increase in such patients. Thus, the adoption of insulin syringes and continuous glucose monitoring devices has increased for close monitoring and optimal management of diabetes.
๐
๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/3740
On the basis of syringe size, 3c/10 cc syringes(0.3ml) segment holds the largest share in market in 2020. The growth of the segment is attributable to the factors such as increase in use of 3/10cc syringes (0.3ml) due to rise in the prevalence of Type 1diabetes across the world are the key factor anticipating the growth of market.
On the basis of disease type, type 2 diabetes segment holds the largest share in market in 2020. The growth of the segment is attributable to the factors such as rise in the adoption of unhealthy lifestyles surge in prevalence of type diabetes across the world are the key factor anticipating the growth of market.
On the basis of end user, hospital & clinics segment holds the largest share in market in 2020 The growth of the segment is attributable to the factors such as rise in geriatric population and large patients pool and surge in prevalence type 2 diabetes across the world, which require the administration of insulin with the help of insulin syringes are the key factor anticipating the growth of market.
๐๐๐ ๐
๐๐๐๐๐๐๐ ๐๐
๐๐๐ ๐๐๐๐๐
- On the basis of syringe size, the 3/10cc syringe segment held the largest market share in 2020, and is expected to remain dominant throughout the forecast period.
- On the basis of end user, the hospital & clinics industries segment held the largest market share in 2020, and is expected to remain dominant throughout the forecast period.
- Region wise, North America is held the largest market share in 2020, and is expected to remain dominant throughout the forecast period
- Asia-Pacific is anticipated to grow at the highest rate in the insulin syringes market during the forecast period, followed by LAMEA
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com